Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, will issue a news release announcing 24-week data from its Phase 2 trial with DSC127 in diabetic foot ulcers at 7:00 a.m. Eastern time Wednesday, May 25 and will hold a conference call to discuss those results at 11:00 a.m. Eastern time that same day.

To participate in the conference call, from the U.S. please dial (888) 563-6275 and from outside the U.S. please dial (706) 634-7417. All listeners should provide passcode 67127770. Individuals interested in listening to the live conference call via the Internet may do so by logging onto the Company’s website, Slides summarizing the clinical data will be available at

Following the completion of the conference call, a replay will be available through June 1, 2011, and can be accessed by dialing (800) 642-1687 from the U.S. or (706) 645-9291 from outside of the U.S. All listeners should provide passcode 67127770. The webcast will also be available on the Company’s website for 30 days.

About Derma Sciences, Inc

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace, traditional dressings, advanced wound care dressings, and pharmaceutical wound care products. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale, randomized controlled trial involving 108 subjects with leg ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for infection prevention. Derma Sciences has successfully completed a Phase 2 clinical trial in diabetic foot ulcer healing with DSC127, a novel pharmaceutical drug under development for accelerated wound healing and scar reduction. For more information please visit

Copyright Business Wire 2010